Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report)’s stock price traded up 4.7% during trading on Friday . The stock traded as high as $24.26 and last traded at $24.43. 77,954 shares changed hands during trading, a decline of 90% from the average session volume of 756,200 shares. The stock had previously closed at $23.33.
Analyst Ratings Changes
Several analysts recently issued reports on PCRX shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC boosted their price target on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays dropped their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $24.50.
Check Out Our Latest Report on Pacira BioSciences
Pacira BioSciences Trading Up 5.1 %
Institutional Investors Weigh In On Pacira BioSciences
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in shares of Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after purchasing an additional 198,936 shares during the last quarter. Pacer Advisors Inc. grew its position in Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after buying an additional 2,799,434 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after buying an additional 288,662 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Pacira BioSciences during the 3rd quarter valued at $793,000. Finally, Empowered Funds LLC bought a new stake in shares of Pacira BioSciences during the 3rd quarter worth $3,286,000. 99.73% of the stock is currently owned by institutional investors.
Pacira BioSciences Company Profile
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Further Reading
- Five stocks we like better than Pacira BioSciences
- What is diluted earnings per share (Diluted EPS)?
- Bloom Energy: Powering the Future With Decentralized Energy
- 3 Small Caps With Big Return Potential
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.